A patient population admitted to the hospital for either SLE or RA was surveyed for the subsequent development of neoplasms. The frequency of neoplasm in SLE patients appeared to be exaggerated, whereas the frequency of subsequent neoplasm in rheumatoid patients was unexpectedly low. A paucity of nephritis in the SLE group was noted. Further reports are encouraged so that the magnitude of the risk of malignancy developing with immunosuppressive therapy can be more precisely ascertained.
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A patient population admitted to the hospital for either SLE or RA was surveyed for the subsequent development of neoplasms. The frequency of neoplasm in SLE patients appeared to be exaggerated, whereas the frequency of subsequent neoplasm in rheumatoid patients was unexpectedly low. A paucity of nephritis in the SLE group was noted. Further reports are encouraged so that the magnitude of the risk of malignancy developing with immunosuppressive therapy can be more precisely ascertained.
Laboratory abnormalities suggesting that autoimmune mechanisms are responsible for some of the lesions seen with several of the connective tissue diseases have led to use of immunosuppressive drugs in the management of these disorders. Concern that such agents
MATERIALS AND METHODS
The patient populations to be compared were selected by computer retrieval of all medical records of hospital admissions for systemic lupus erythematosus (SLE), discoid lupus erythematosus (DLE), rheumatoid arthritis (RA), and benign essential hypertension during the period 1955-1974. Patient diagnoses are coded by the ICDA and HICDA systems and stored in an IBM 370/145 computer using the Mark IV Informatic's data retrieval system. Only those hypertensive patients were included whose blood pressure abnormality was the primary diagnosis at the initial admission. Patients identified in the four primary disease categories were then cross-checked against the tumor registry of the University of Michigan Hospital. This registry now includes data concerning approximately 62,000 malignant and certain benign neoplasms. Recorded data include information on the patients' sex, age, race, age at onset of neoplasm, location and histology of neoplasm, extent of disease, type of treatment, and length of survival ( 5 ) . The relative frequency of neoplasm in the population visiting the University of Michigan Hospital over the study period has been approximately 2-3% of total hospital registrations ( Table 1 ) .
Patients with neoplasms included in this study met the American Rheumatism Association's criteria for SLE (6) or for definite/classic RA (7). This study attempted to focus on those patients with one of the four primary diagnoses who developed neoplasms 1 year or more after the primary diagnosis. Thus two records were excluded because the neoplasm preceded connective tissue disease, or because the diagnosis of both was established within the same year. Nineteen patients with other connective tissue diseases or with nonmalignant tumors were excluded from the present study. One hundred forty-two records from hypertensive patients were rejected either because the neoplasm preceded the hypertension or because the diagnoses were made at the same time. The age, sex, and racial characteristics of the four primary diagnostic groups a t the time of initial hospital admission are summarized in Table 2 .
Although there are problems inherent in a retrospective record review, it is likely that these data may help to establish the frequency (period prevalence) of occurrence of neoplasia in SLE and RA. Clearly, a study of this nature presumes that neoplasms developing in the rheumatic and hypertensive patients would be known at the University Hos- 
1955-1974.
Both clinics see 4,000-5,500 outpatients per year, over 80% of which are follow-up (return) visits.
RESULTS

Lupus Erythematosus
A total of 737 patients were admitted to the hospital with the diagnosis of lupus erythematosus during the 20-year review period. Patients with chronic discoid lupus (DLE) constituted approximately onethird of the group (253 patients) and were considered separately. Four neoplasms were found in the DLE group (Table 3) . A total of 484 patients with SLE were at risk. SLE patients with neoplasms had a mean age of 42.5 years (* SD = 9.8 years; range: 32-63 years). The 18 SLE patients with neoplasms included 13 females (10 whites, 3 blacks). The mean time from diagnosis of systemic lupus to diagnosis of neoplasm was 7 years, with a range of 1-18 years (Figure 1) .
The several types of malignancies found are recorded in Table 3 . As noted in Table 4 , nearly 4% of this particular SLE population ultimately developed some kind of malignancy. Table 5 records the frequency of the different classification criteria for SLE, and Figure 2 depicts the frequency distribution of the number of diagnostic criteria detected in individual patients. It is apparent that most patients had more than the minimum criteria (6) required for the diagnosis of SLE. Laboratory abnormalities, shown in were those expected with SLE. All patients were treated with adrenal corticosteroids, but only 1 received 60 mg of prednisone per day or more, and for only I month. The other patients generally received 20 mg of prednisone or its equivalent daily, or less. Only 1 patient, a 46-year-old woman with thrombocytopenia and hemolytic anemia, had been treated with immunosuppressive drugs. She had received cyclophosphamide, 100 mg daily for 6 days, and 1 year earlier had been treated for 2 months with 6-mercaptopurine, 50 mg daily. Her last exposure to these medications had been 18 months before the diagnosis of adenocarcinoma of the lung.
Rheumatoid Arthritis
A total of 2,867 patients were admitted to the hospital with the diagnosis of rheumatoid arthritis during the study period. Seventeen neoplasms were found in * Some patients had more than one abnormality. this group of patients, an overall "period prevalence" of approximately 0.6%. Patient ages ranged from 45 to 79 with a mean of 61.2 f 8.3 years. Nine patients were males, of whom 2 were black, and all 8 females were white. At the time of diagnosis of neoplasm, these patients had had RA for a mean of 10 years (range: 1-23 years; see Figure I ). The types of malignancies found in the RA group are shown in Table 3 . Table 7 records the clinical characteristics of the patients with RA. Laboratory findings in the RA patients are presented in Table 8 . There were 2 patients with clinical and laboratory features compatible with Felty's syndrome. One had a melanoma and the other had a basal cell carcinoma of the skin and squamous cell carcinoma of the lung. Two patients had Sjogren's syndrome; 1 developed oat cell carcinoma of the lung and the other had adenocarcinoma of the uterus. Interestingly, 7 of the 17 patients with both RA and neoplasm had family members with neoplasms, but none was of the same type found in the proband. Ten of 17 patients in this group had been treated with adrenal corticosteroids, 3 in "bursts" and the other 7 continuously for 1-20 years. The type of malignancy in these patients varied, but three-quarters of the patients with basal cell carcinoma had been treated with prednisone. None of the RA patients had received other forms of immunosuppressive therapy.
Benign Essential Hypertension
Among 3,295 persons admitted to the University Hospital primarily for their hypertension during the period 1955-1974, 44 (1.36%) subsequently developed neoplasms that were recorded in the tumor registry. There were 24 female patients with a mean age of 5 1 f 1 1.3 years and 20 male patients with a mean age of 57.9 f 9.1 years.
DISCUSSION
Studies by Penn, which led to the development of an informal tumor registry for renal transplant patients, documented an increased incidence of neoplasia in patients treated with immunosuppressive drugs for prolonged periods (3). Leibowitz and Schwartz (2) have also suggested that neoplasia can be anticipated as a complication of immunosuppressive therapy. It is important to determine the baseline frequency of neoplasia in association with the connective tissue diseases so that the potential increased occurrence of neoplasms in drugtreated cases can be recognized. The neoplasms detected in this study comprise a general spectrum of histologic types of malignancy with no emphasis on lymphoproliferative disorders. However a referral center seeing patients with severe and complicated diseases may yield data not representative of the general population of SLE and RA patients.
Data from the SLE patients with neoplasms nevertheless deserve special comment. This group was unusual in that only 1 patient had renal disease. Canoso and Cohen noted that 50% of their patients had renal disease (4). Although this finding may mean that nephritis causes death before neoplasia can develop, more subtle mechanisms influencing susceptibility to tumor development cannot be excluded. Walker and Bole have reported an increased occurrence of lymphomas in NZB/NZW mice treated with long-term cyclophosphamide to suppress nephritis (18) . In contrast to the RA patients, those with SLE developed their neoplasms at a younger mean age.
The sex distribution of SLE patients with neoplasms paralleled the usual sex ratio in this disease. However more than half the RA patients with malignancy were males. The apparent "protection" against neoplasia offered by RA (or aspirin?) is interesting. An alternative possibility might hold that benign essential hypertension, or its treatment modalities, are associated with a higher than normal frequency of malignancy. Clearly, a control study with a population group simply followed for periodic health examinations would be valuable. No special clinical characteristics, other than the decreased frequency of nephritis in SLE cases, were identified in the DLE, SLE, or RA patients that were predictive of later development of malignancies.
